sr-144528 has been researched along with Parkinson-Disease* in 1 studies
1 other study(ies) available for sr-144528 and Parkinson-Disease
| Article | Year |
|---|---|
Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson's Disease.
The 3-hydroxyquinone derivative of the non-psychotrophic phytocannabinoid cannabigerol, so-called VCE-003.2, and some other derivatives have been recently investigated for neuroprotective properties in experimental models of Parkinson's disease (PD) in mice. The pharmacological effects in those models were related to the activity on the peroxisome proliferator-activated receptor-γ (PPAR-γ) and possibly other pathways. In the present study, we investigated VCE-004.8 (formulated as EHP-101 for oral administration), the 3-hydroxyquinone derivative of cannabidiol (CBD), with agonist activity at the cannabinoid receptor type-2 (CB Topics: Administration, Oral; Animals; Benzamides; Camphanes; Cannabidiol; Cannabinoids; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotection; Oxidopamine; Parkinson Disease; PPAR gamma; Pyrazoles; Pyridines; Quinones; Tyrosine 3-Monooxygenase | 2021 |